Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neoplasms 50Lymphoma 30Lung Neoplasms 29Breast Neoplasms 28Prostatic Neoplasms 25Multiple Myeloma 25Melanoma 21Lymphoma, Non-Hodgkin 20Carcinoma, Non-Small-Cell Lung 20Ovarian Neoplasms 19Leukemia, Myeloid, Acute 19Glioma 18Pancreatic Neoplasms 17Neoplasm Metastasis 17Urinary Bladder Neoplasms 15Hematologic Neoplasms 15Colorectal Neoplasms 15Carcinoma, Renal Cell 15Sarcoma 14Burkitt Lymphoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neuroblastoma 13Colonic Neoplasms 12Carcinoma 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Myelodysplastic Syndromes 11Leukemia, Lymphocytic, Chronic, B-Cell 11Ependymoma 11Brain Neoplasms 11

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thyroid Cancer, Papillary × 30 days × Clear all
NCT03914300 2026-06-01

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled 11 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡